Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke.

Wilson LM, Anderson TS. Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke. Neurology. 2025 Jun 24; 104(12):e213739, DOI: 10.1212/WNL.0000000000213739.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


Abstract:

OBJECTIVES: The 2024 American Heart Association and American Stroke Association stroke prevention guideline newly recommended glucose-like peptide-1 receptor agonists (GLP-1s) for primary prevention of stroke in patients with diabetes and elevated risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to characterize the population newly recommended GLP-1s. METHODS: This cross-sectional study included adults aged 30-79 years without previous stroke and with diabetes who participated in the National Health and Nutrition Examination Survey from 2017 to March 2020. Participants were guideline-eligible for GLP-1 if they had HbA1C 7% and existing or a high 10-year risk of ASCVD. Current GLP-1 users were identified by in-home review of medications. Data were weighted to be nationally representative. RESULTS: The study included 1,104 participants (mean age 60 years; 45% female) representing 23.5 million (95% CI, 21.2 million-25.8 million) US adults with diabetes. Stroke prevention guideline recommendations would apply to 4.9 million (95% CI, 3.7 million-6.0 million) US adults. GLP-1 eligibility was more common among older adults, men, and those with private insurance or Medicare. Only 6.8% (95% CI 3.3%-10.7%) of adults meeting recommendations were taking a GLP-1. DISCUSSION: Almost 5 million Americans with diabetes would qualify for GLP-1 use for primary prevention of stroke, but current use among this population is very low.




Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.
<--- --->